Publications by authors named "Gerda Weits"

Claim this Profile
P
Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes.
Leanne J Kosse, Gerda Weits, Harald E Vonkeman, Sander W Tas, Frank Hoentjen

Expert Opin Drug Saf· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands.
Linda Härmark, Gerda Weits, Rietje Meijer, Federica Santoro, G Niklas Norén

Drug Saf· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics.
Leanne J Kosse, Gerda Weits, Harald E Vonkeman, Phyllis I Spuls, Bart J F Van Den Bemt

Expert Opin Drug Saf· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands.
Linda Härmark, Gerda Weits, Rietje Meijer, Federica Santoro, G Niklas Norén

Drug Saf· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of European Patient Organizations in Pharmacovigilance.
Cristiano Matos, Gerda Weits, Florence van Hunsel

Drug Saf· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collaboration between patient and pharmacovigilance organizations to gain insight into adults' experiences with drug use and ADRs for the treatment of ADHD.
Gerda Weits, Linda Härmark, Jenny Hartman, Agnes Kant

Expert Opin Drug Saf· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis